LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition MT
CymaBay Therapeutics, Inc. Announces Board Changes CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index CI
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc.. CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index CI
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires MT
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar MT
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Leerink Partners Downgrades CymaBay Therapeutics to Market Perform From Outperform, Adjusts PT to $32.50 From $26 MT
UBS Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts Price Target to $32.50 From $25 MT
LifeSci Capital Downgrades CymaBay Therapeutics to Market Perform From Outperform MT
Piper Sandler Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $33 MT
North American Morning Briefing :Stock Futures -2- DJ
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29 MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy MT
JonesTrading Downgrades CymaBay Therapeutics to Hold From Buy MT
Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $30 MT
William Blair Downgrades CymaBay Therapeutics to Market Perform From Outperform MT
BTIG Downgrades CymaBay Therapeutics to Neutral From Buy MT
HC Wainwright Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts PT to $32.50 From $28 MT
Chart CymaBay Therapeutics, Inc.
More charts
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.
More about the company
  1. Stock Market
  2. Equities
  3. CBAY Stock
  4. News CymaBay Therapeutics, Inc.
  5. BTIG Downgrades CymaBay Therapeutics to Neutral From Buy